EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies

Eunhye Jeon, Jaewon Song, Taebo Sim

Future Medicinal Chemistry · 2026

DOI: 10.1080/17568919.2026.2719780 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, 2026. Verfasst von Eunhye Jeon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Proto-Oncogene Proteins p21(ras), Drug Discovery, Drug Design. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Education (MOE) and the Seoul Metropolitan Government, Ministry of Health & Welfare, Republic of Korea, Ministry of Science and ICT, Ministry of Trade, Industry and Energy and Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS is one of the most frequently mutated oncogenes in human cancers, with KRAS G12D representing the predominant mutation in pancreatic ductal adenocarcinoma and a major driver of colorectal and lung cancers. Although KRAS was long considered "undruggable" due to structural and biochemical constraints, the discovery of the switch-II pocket enabled the development of direct KRAS inhibitors, leading to the clinical success of KRAS G12C-targeted therapies. Building on this breakthrough, advances have been made in KRAS G12D-targeted drug development, including potent non-covalent inhibitors such as MRTX1133, HRS-4642, LY3962673, and INCB161734, as well as RAS(ON) tri-complex inhibitors such as RMC-9805. Pan-RAS and pan-KRAS inhibitors have emerged as a promising strategy to overcome the limitations of mutation-specific KRAS inhibitors, including restricted mutation coverage and acquired resistance. Among the developed pan-RAS inhibitors, RMC-6236 is the most advanced candidate in clinical development. In parallel, targeted protein degradation strategies, particularly PROTAC-based degraders such as ASP3082 and RP03707, have emerged as promising alternatives to overcome resistance and improve therapeutic durability. Combination strategies involving EGFR inhibitors, chemotherapy, and immunotherapy are also expanding clinical potential. This review summarizes recent progress in KRAS G12D-targeted inhibitors and degraders, highlighting current challenges and future opportunities for improving KRAS-directed cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsProto-Oncogene Proteins p21(ras)Drug DiscoveryDrug DesignOncogene Protein p21(ras)HumansProteolysis Targeting ChimeraMutationNeoplasms

Stichwörter der Autor:innen

KRAS mutationPROTACinhibitorswitch-II pockettargeted therapy

Substanzen

Antineoplastic AgentsProto-Oncogene Proteins p21(ras)KRAS protein, humanProteolysis Targeting ChimeraOncogene Protein p21(ras)

Autor:innen und Institutionen

  • Department of Medical Science, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Biomedical Sciences, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Graduate School of Clinical Drug Discovery & Development, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Clinical Candidate Discovery & Development Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.

Förderung

  • Ministry of Education (MOE) and the Seoul Metropolitan Government
  • Ministry of Health & Welfare, Republic of Korea
  • Ministry of Science and ICT, Ministry of Trade, Industry and Energy and Ministry of Health and Welfare
  • the Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea

Zitieren

APA

Jeon, E., Song, J., & Sim, T. (2026). Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2026.2719780

Vancouver

Jeon E, Song J, Sim T. Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies. Future Medicinal Chemistry. 2026. doi:10.1080/17568919.2026.2719780

BibTeX
@article{Jeon2026,
  author = {Jeon, Eunhye and Song, Jaewon and Sim, Taebo},
  title = {Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies},
  journal = {Future Medicinal Chemistry},
  year = {2026},
  doi = {10.1080/17568919.2026.2719780}
}
Kostenlos starten →